{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:02:28Z","timestamp":1789243348709,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\/glucose cotransporter-2 inhibitors (SGLT2i) are associated with cardiovascular benefits. The aim of this systematic review and meta-analysis is to summarize the influence of SGLT2i on the incidence of acute kidney injury (AKI), and to ascertain whether it is affected by confounding variables such as age, baseline renal function and concurrent use of renin-angiotensin-aldosterone system inhibitors (RAASi) or mineralocorticoid receptor antagonists (MRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials comparing the influence of SGLT2i versus placebo\/blank treatment on AKI in the adult population. A fixed-effect model was used if the heterogeneity was not significant; otherwise, a randomized-effect model was used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen studies comprising 98,989 patients were included. Compared with placebo\/blank treatment, treatment with SGLT2i significantly reduced the risk of AKI (risk ratio [RR]: 0.78, 95% confidence interval [CI]: 0.71 to 0.84,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). Subgroup analysis suggested consistent results in patients with diabetes, chronic kidney disease, and heart failure (for subgroup difference,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.32). Finally, univariate meta-regression suggested that the influence of SGLT2i on the risk of AKI was not significantly modified by variables such as age (coefficient: 0.011,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.39), baseline estimated glomerular filtration rate (coefficient: \u22120.0042,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.13) or concomitant use of RAASi (coefficient: 0.0041,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.49) or MRA (coefficient: \u22120.0020,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.34).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i may be effective in reducing the risk of AKI, and the effect might not be modified by age, baseline renal function and concurrent use of RAASi or MRA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1372421","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:39:27Z","timestamp":1719275967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Influence of sodium\/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40620-022-01422-w","article-title":"Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?","volume":"36","author":"Copur","year":"2023","journal-title":"J. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13098-023-01107-9","article-title":"The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study","volume":"15","author":"Feitosa","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3390\/biomedicines11072085","article-title":"Cardiovascular diseases: therapeutic potential of SGLT-2 inhibitors","volume":"11","author":"Frak","year":"2023","journal-title":"Biomedicines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"926979","DOI":"10.3389\/fcvm.2022.926979","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: a meta-analysis of randomized controlled clinical trials","volume":"9","author":"Gong","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B15","volume-title":"Cochrane Handbook for systematic reviews of interventions version 6.2","author":"Higgins","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1097\/FJC.0000000000001268","article-title":"Dapagliflozin attenuates contrast-induced acute kidney injury by regulating the HIF-1\u03b1\/HE4\/NF-\u03baB pathway","volume":"79","author":"Huang","year":"2022","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40261-021-01006-9","article-title":"Correlations between SGLT-2 inhibitors and acute renal failure by signal detection using FAERS: stratified analysis for reporting country and concomitant drugs","volume":"41","author":"Katsuhara","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3390\/pharmaceutics15071995","article-title":"SGLT2 inhibitors in the treatment of diabetic kidney disease: more than just glucose regulation","volume":"15","author":"Klen","year":"2023","journal-title":"Pharmaceutics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41598-020-64380-y","article-title":"Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats","volume":"10","author":"Kuno","year":"2020","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1174692","DOI":"10.3389\/fendo.2023.1174692","article-title":"Comprehensive review of SGLT2 inhibitors\u2019 efficacy through their diuretic mode of action in diabetic patients","volume":"14","author":"Lam-Chung","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/ejendo\/lvad078","article-title":"Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"189","author":"Lin","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","volume":"29","author":"Maayah","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jamacardio.2022.2006","article-title":"Efficacy and safety of dapagliflozin according to background use of cardiovascular medications in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial","volume":"7","author":"Oyama","year":"2022","journal-title":"JAMA Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"","journal-title":"BMJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.ajkd.2020.01.015","article-title":"Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report","volume":"76","author":"Phadke","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"14791641211011016","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc. Dis. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2020.03.019","article-title":"Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study","volume":"76","author":"Rampersad","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1111\/dom.15193","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"25","author":"Rigato","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.11220720","article-title":"Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury","volume":"16","author":"Zhao","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372421\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:39:29Z","timestamp":1719275969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372421\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":49,"alternative-id":["10.3389\/fphar.2024.1372421"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1372421","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"article-number":"1372421"}}